{"id":"NCT02184572","sponsor":"GlaxoSmithKline","briefTitle":"Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age","officialTitle":"Safety and Immunogenicity Study of GSK Biologicals' Measles-mumps-rubella (MMR) Vaccine (209762) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine, in Healthy Children 12 to 15 Months of Age","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-08-25","primaryCompletion":"2015-08-14","completion":"2015-12-22","firstPosted":"2014-07-09","resultsPosted":"2018-07-03","lastUpdate":"2021-01-07"},"enrollment":1742,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Measles; Mumps; Rubella","Measles-Mumps-Rubella Vaccine"],"interventions":[{"type":"BIOLOGICAL","name":"Priorix","otherNames":["GSK Biologicals' live attenuated measles","mumps and rubella (MMR) vaccine"]},{"type":"BIOLOGICAL","name":"M-M-R II","otherNames":["MMR vaccine live (M-M R II","Merck & Co.","Inc.","or M-M-R VaxPro","Sanofi Pasteur/Merck Sharp and Dohme [SPMSD])"]},{"type":"BIOLOGICAL","name":"Varivax","otherNames":["Merck & Co. Inc.'s Varicella virus vaccine","live"]},{"type":"BIOLOGICAL","name":"Havrix","otherNames":["GSK Biologicals' Hepatitis A vaccine","inactivated"]},{"type":"BIOLOGICAL","name":"Prevnar 13","otherNames":["Pfizer Inc.'s Pneumococcal 13-valent conjugate vaccine (diphtheria CRM197 protein)"]}],"arms":[{"label":"INV_MMR","type":"EXPERIMENTAL"},{"label":"COM_MMR","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the immunogenicity and safety of GSK Biologicals' trivalent MMR (Priorix), comparing it to Merck's MMR vaccine (M-M-R II), which is approved for use in the US in healthy children 12 to 15 months of age.","primaryOutcome":{"measure":"Number of Subjects Reporting Fever After MMR (Priorix or M-M-R II/M-M-R VaxPro [Lot 1 or Lot 2]) Vaccination","timeFrame":"During Day 5 to Day 12 post-vaccination period","effectByArm":[{"arm":"INV_MMR Group","deltaMin":47,"sd":null},{"arm":"COM_MMR Group","deltaMin":17,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"12 Months","sex":"ALL","healthyVolunteers":true,"inclusionCount":5,"exclusionCount":17},"locations":{"siteCount":95,"countries":["United States","Estonia","Finland","Puerto Rico","Taiwan"]},"refs":{"pmids":["30118386"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":24,"n":1164},"commonTop":["Irritability","Somnolence","Decreased appetite","Pyrexia","Injection site pain"]}}